01:35 PM EST, 11/06/2025 (MT Newswires) -- (Updates with additional details in the third to fifth paragraphs.)

Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) have reached agreements to reduce prices for a number of weight-loss and diabetes drugs, including Ozempic, Wegovy, Zepbound and Orforglipron under the government's TrumpRx program, the White House said in a statement Thursday.

Prices for Ozempic and Wegovy will decline to $350 from $1,000 and $1,350, respectively, while Zepbound and Orforglipron will fall to an average of $346 from $1,086 when purchased through TrumpRx, the White House added.

Medicare will cover Wegovy and Zepbound for obesity-related conditions for the first time at a $245 monthly price, with beneficiaries paying a $50 co-pay, and state Medicaid programs gaining similar access, the administration said.

Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) will also cut costs on other treatments, such as Emgality, Trulicity, and insulin products, and will guarantee most-favored-nation prices on new drugs, according to the statement.

Novo Nordisk ( NVO ) pledged an additional $10 billion to expand US manufacturing, while Eli Lilly ( LLY ) will invest at least $27 billion to strengthen domestic production, the statement added.

Price: 918.45, Change: -7.36, Percent Change: -0.79